Omeros
About OmerosPipelineInvestorsNews


Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

 
Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$11.09
Change (%) Stock is Down 0.5 (4.31%)
Volume222,510
Data as of 02/05/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
DateTitle  
01/15/16Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference
SEATTLE--(BUSINESS WIRE)--Jan. 15, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% will be the focus of a series of ... 
 Printer Friendly Version
01/06/16Omeros Announces $70 Million New Credit Facility and Conversion of Contract Sales Force to In-House Team
SEATTLE--(BUSINESS WIRE)--Jan. 6, 2016-- Omeros Corporation (NASDAQ:OMER) today announced that it has closed a non-dilutive senior credit facility with Oxford Finance and East West Bank. The new credit facility consists of a $50.0 million term loan drawn by the company at closing and the ability, subject to the satisfaction of certain conditions including achievement of certain net revenue milestones for the company’s product Omidria® (phenylephri... 
 Printer Friendly Version
11/09/15Omeros Corporation Reports Third Quarter 2015 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE, Nov. 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2015, which in... 
 Printer Friendly Version
11/02/15Omeros Corporation to Announce Third Quarter 2015 Financial Results on November 9, 2015
SEATTLE, Nov. 2, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its third quarter 2015 financial results for the period ended September 30, 2015, on Monday, November 9, 2015, after marke... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2014 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.